Login to Your Account

Other News To Note

Tuesday, May 24, 2011
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., said the FDA scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee meeting June 17 to review the biologics license application (BLA) for VEGF Trap-Eye (aflibercept ophthalmic solution) for wet age-related macular degeneration. Regeneron submitted the BLA in February. VEGF Trap-Eye is partnered with Berlin-based Bayer AG.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription